Sildenafil Citrate for the Prevention of High Altitude Hypoxic Pulmonary Hypertension: Double Blind, Randomized, Placebo-Controlled Trial
Publication: High Altitude Medicine & Biology
Volume 12, Issue Number 3
Abstract
Bates, Matthew G.D., A.A. Roger Thompson, Kenneth Baillie, Andrew I. Sutherland, John B. Irving, NikhillHirani, and David J. Webb. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial. High Alt. Med. Biol. 12:207–214.—Exaggerated hypoxic pulmonary vasoconstriction is a key factor in the development of high altitude pulmonary edema (HAPE). Due to its effectiveness as a pulmonary vasodilator, sildenafil has been proposed as a prophylactic agent against HAPE. By conducting a parallel-group double blind, randomized, placebo-controlled trial, we investigated the effect of chronic sildenafil administration on pulmonary artery systolic pressure (PASP) and symptoms of acute mountain sickness (AMS) during acclimatization to high altitude. Sixty-two healthy lowland volunteers (36 male; median age 21 years, range 18 to 31) on the Apex 2 research expedition were flown to La Paz, Bolivia (3650 m), and after 4–5 days acclimatization ascended over 90 min to 5200 m. The treatment group (n=20) received 50 mg sildenafil citrate three times daily. PASP was recorded by echocardiography at sea level and within 6 h, 3 days, and 1 week at 5200 m. AMS was assessed daily using the Lake Louise Consensus symptom score. On intention-to-treat analysis, there was no significant difference in PASP at 5200 m between sildenafil and placebo groups. Median AMS score on Day 2 at 5200 m was significantly higher in the sildenafil group (placebo 4.0, sildenafil 6.5; p=0.004) but there was no difference in prevalence of AMS between groups. Sildenafil administration did not affect PASP in healthy lowland subjects at 5200 m but AMS was significantly more severe on Day 2 at 5200 m with sildenafil. Our data do not support routine prophylactic use of sildenafil to reduce PASP at high altitude in healthy subjects with no history of HAPE. Trials registration number: NCT00627965
Get full access to this article
View all available purchase options and get full access to this article.
References
Ahn HSFoster MCable MPitts BJSybertz EJ1991. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissuesAdv Exp Med Biol308191-197. Ahn HS, Foster M, Cable M, Pitts BJ, and Sybertz EJ. (1991). Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 308:191–197.
Allemann YSartori CLepori MPierre SMelot CNaeije RScherrer UMaggiorini M2000. Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitudeAm J Physiol Heart Circ Physiol279H2013-2016. Allemann Y, Sartori C, Lepori M, Pierre S, Melot C, Naeije R, Scherrer U, and Maggiorini M. (2000). Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol 279:H2013–2016.
Baillie JKThompson AARBates MGDSchnopp MFSimpson APartridge RW2004. The Chacaltaya High Altitude LaboratoryJ R Coll Phys Edin34130-133. Baillie JK, Thompson AAR, Bates MGD, Schnopp MF, Simpson A, and Partridge RW. (2004). The Chacaltaya High Altitude Laboratory. J R Coll Phys Edin 34:130–133.
Baillie JKThompson AARIrving JBBates MGDSutherland AIMacNee WMaxwell SRWebb DJ2009. Oral antioxidant supplementation does not prevent acute mountain sickness: Double blind, randomized placebo-controlled trialQJM102341-348. Baillie JK, Thompson AAR, Irving JB, Bates MGD, Sutherland AI, MacNee W, Maxwell SR, and Webb DJ. (2009). Oral antioxidant supplementation does not prevent acute mountain sickness: Double blind, randomized placebo-controlled trial. QJM 102:341–348.
Bartsch PMairbaurl HMaggiorini MSwenson ER2005. Physiological aspects of high-altitude pulmonary edemaJ App Physiol.981101-1110. Bartsch P, Mairbaurl H, Maggiorini M, and Swenson ER. (2005). Physiological aspects of high-altitude pulmonary edema. J App Physiol. 98:1101–1110.
Basnyat BHargrove JHolck PSSrivastav SAlekh KGhimire LVPandey KGriffiths AShankar RKaul K et al.2008. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humansHigh Alt Med Biol9209-216. Basnyat B, Hargrove J, Holck PS, Srivastav S, Alekh K, Ghimire LV, Pandey K, Griffiths A, Shankar R, Kaul K, et al. (2008). Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol 9:209–216.
Beavo JA1995. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoformsPhysiol Rev75725-748. Beavo JA. (1995). Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725–748.
Busch TBartsch PPappert DGrunig EHildebrandt WElser HFalke KJSwenson ER2001. Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edemaAm J Respir Crit Care Med163368-373. Busch T, Bartsch P, Pappert D, Grunig E, Hildebrandt W, Elser H, Falke KJ, and Swenson ER. (2001). Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am J Respir Crit Care Med 163:368–373.
Duplain HSartori CLepori MEgli MAllemann YNicod PScherrer U2000. Exhaled nitric oxide in high-altitude pulmonary edema: Role in the regulation of pulmonary vascular tone and evidence for a role against inflammationAm J Respir Crit Care Med162221-224. Duplain H, Sartori C, Lepori M, Egli M, Allemann Y, Nicod P, and Scherrer U. (2000). Exhaled nitric oxide in high-altitude pulmonary edema: Role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med 162:221–224.
Faoro VHuez SGiltaire SPavelescu Avan Osta AMoraine JJGuenard HMartinot JBNaeije R2007a. Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudesJ Appl Physiol1031161-1165. Faoro V, Huez S, Giltaire S, Pavelescu A, van Osta A, Moraine JJ, Guenard H, Martinot JB, and Naeije R. (2007a). Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes. J Appl Physiol 103:1161–1165.
Faoro VLamotte MDeboeck GPavelescu AHuez SGuenard HMartinot JBNaeije R2007b. Effects of sildenafil on exercise capacity in hypoxic normal subjectsHigh Alt Med Biol8155-163. Faoro V, Lamotte M, Deboeck G, Pavelescu A, Huez S, Guenard H, Martinot JB, and Naeije R. (2007b). Effects of sildenafil on exercise capacity in hypoxic normal subjects. High Alt Med Biol 8:155–163.
Galie NGhofrani HATorbicki ABarst RJRubin LJBadesch DFleming TParpia TBurgess GBranzi A et al.2005. Sildenafil citrate therapy for pulmonary arterial hypertension[Erratum appears in N Engl J Med 2006 Jun 1;354(22):2400-1]N Engl J Med3532148-2157. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension.[Erratum appears in N Engl J Med 2006 Jun 1;354(22):2400-1]. N Engl J Med 353:2148–2157.
Ghofrani HAReichenberger FKohstall MGMrosek EHSeeger TOlschewski HSeeger WGrimminger F2004. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: A randomized, double-blind, placebo-controlled crossover trialAnn Intern Med141169-177. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, Seeger W, and Grimminger F. (2004). Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: A randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 141:169–177.
Ghofrani HASchermuly RTRose FWiedemann RKohstall MGKreckel AOlschewski HWeissmann NEnke BGhofrani S et al.2003. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertensionAm J Respir Crit Care Med1671139-1141. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, et al. (2003). Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167:1139–1141.
Hohne CPickerodt PAFrancis RCBoemke WSwenson ER2007. Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibitionAm J Physiol Lung Cell Mol Physiol292L178-184. Hohne C, Pickerodt PA, Francis RC, Boemke W, and Swenson ER. (2007). Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition. Am J Physiol Lung Cell Mol Physiol 292:L178–184.
Hsu ARBarnholt KEGrundmann NKLin JHMcCallum SWFriedlander AL2006. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxiaJ Appl Physiol1002031-2040. Hsu AR, Barnholt KE, Grundmann NK, Lin JH, McCallum SW, and Friedlander AL. (2006). Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physiol 100:2031–2040.
Kruuse CThomsen LLBirk SOlesen J2003. Migraine can be induced by sildenafil without changes in middle cerebral artery diameterBrain126241-247. Kruuse C, Thomsen LL, Birk S, and Olesen J. (2003). Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126:241–247.
Lin GXin ZCLue TFLin CS2003. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapismJ Urol170S15-18discussion S19. Lin G, Xin ZC, Lue TF, and Lin CS. (2003). Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol 170:S15–18; discussion S19.
Maggiorini MBrunner-La Rocca HPPeth SFischler MBohm TBernheim AKiencke SBloch KEDehnert CNaeije R et al.2006. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A randomized trial[Summary for patients in Ann Intern Med 2006 Oct 3;145(7):I28; PMID: 17015863]Ann Intern Med145497-506. Maggiorini M, Brunner-La Rocca HP, Peth S, Fischler M, Bohm T, Bernheim A, Kiencke S, Bloch KE, Dehnert C, Naeije R, et al. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A randomized trial.[Summary for patients in Ann Intern Med 2006 Oct 3;145(7):I28; PMID: 17015863]. Ann Intern Med 145:497–506.
Maggiorini MMelot CPierre SPfeiffer FGreve ISartori CLepori MHauser MScherrer UNaeije R2001. High-altitude pulmonary edema is initially caused by an increase in capillary pressureCirculation1032078-2083. Maggiorini M, Melot C, Pierre S, Pfeiffer F, Greve I, Sartori C, Lepori M, Hauser M, Scherrer U, and Naeije R. (2001). High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 103:2078–2083.
Michelakis ETymchak WLien DWebster LHashimoto KArcher S2002. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxideCirculation1052398-2403. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, and Archer S. (2002). Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398–2403.
Michelakis EDTymchak WNoga MWebster LWu XCLien DWang SHModry DArcher SL2003. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertensionCirculation1082066-2069. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, and Archer SL. (2003). Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066–2069.
Pfizer2006. Viagra (Sildenafil)http://pfizer.com/pfizer/download/uspi_viagra.pdfNovember2006. Pfizer. (2006). Viagra (Sildenafil). http://pfizer.com/pfizer/download/uspi_viagra.pdf. Accessed November 2006.
Ricart AMaristany JFort NLeal CPages TViscor G2005. Effects of sildenafil on the human response to acute hypoxia and exerciseHigh Alt. Med Biol643-49. Ricart A, Maristany J, Fort N, Leal C, Pages T, and Viscor G. (2005). Effects of sildenafil on the human response to acute hypoxia and exercise. High Alt. Med Biol 6:43–49.
Richalet JPGratadour PRobach PPham IDechaux MJoncquiert-Latarjet AMollard PBrugniaux JCornolo J2005. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertensionAm J Respir Crit Care Med171275-281. Richalet JP, Gratadour P, Robach P, Pham I, Dechaux M, Joncquiert-Latarjet A, Mollard P, Brugniaux J, and Cornolo J. (2005). Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 171:275–281.
Roach RCBartsch PHackett PHOelz O1993. The Lake Louise acute mountain sickness scoring systemHypoxia and Molecular MedicineJR SuttonCS HoustonG CoatesBurlington, VTQueens City Printers272-274. Roach RC, Bartsch P, Hackett PH, and Oelz O. (1993). The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine. JR Sutton, CS Houston, G Coates, eds. Burlington, VT: Queens City Printers, pp. 272–274.
Rosengarten BSchermuly RTVoswinckel RKohstall MGOlschewski HWeissmann NSeeger WKaps MGrimminger FGhofrani HA2006. Sildenafil improves dynamic vascular function in the brain: Studies in patients with pulmonary hypertensionCerebrovasc Dis21194-200. Rosengarten B, Schermuly RT, Voswinckel R, Kohstall MG, Olschewski H, Weissmann N, Seeger W, Kaps M, Grimminger F, and Ghofrani HA. (2006). Sildenafil improves dynamic vascular function in the brain: Studies in patients with pulmonary hypertension. Cerebrovasc Dis 21:194–200.
Schermuly RTKreisselmeier KPGhofrani HAYilmaz HButrous GErmert LErmert MWeissmann NRose FGuenther A et al.2004. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in ratsAm J Respir Crit Care Med16939-45. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H. Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, et al. (2004). Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169:39–45.
Scherrer UVollenweider LDelabays ASavcic MEichenberger UKleger GRFikrle ABallmer PENicod PBartsch P1996. Inhaled nitric oxide for high-altitude pulmonary edemaN Engl J Med334624-629. Scherrer U, Vollenweider L, Delabays A, Savcic M, Eichenberger U, Kleger GR, Fikrle A, Ballmer PE, Nicod P, and Bartsch P. (1996). Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 334:624–629.
Swenson ERMaggiorini MMongovin SGibbs JSGreve IMairbaurl HBartsch P2002. Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factorJAMA2872228-2235. Swenson ER, Maggiorini M, Mongovin S, Gibbs JS, Greve I, Mairbaurl H, and Bartsch P. (2002). Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. JAMA 287:2228–2235.
Teppema LJBalanos GMSteinback CDBrown ADFoster GEDuff HJLeigh RPoulin MJ2007. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxiaAm J Respir Crit Care Med175277-281. Teppema LJ, Balanos GM, Steinback CD, Brown AD, Foster GE, Duff HJ, Leigh R, and Poulin MJ. (2007). Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. Am J Respir Crit Care Med 175:277–281.
Weimann JUllrich RHromi JFujino YClark MWBloch K.DZapol WM2000. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertensionAnesthesiology921702-1712. Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch K.D, and Zapol WM. (2000). Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92:1702–1712.
Zhao LMason NAMorrell NWKojonazarov BSadykov AMaripov AMirrakhimov MMAldashev AWilkins MR2001. Sildenafil inhibits hypoxia-induced pulmonary hypertensionCirculation104424-428. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, and Wilkins MR. (2001). Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104:424–428.
Information & Authors
Information
Published In
High Altitude Medicine & Biology
Volume 12 • Issue Number 3 • Fall 2011
Pages: 207 - 214
PubMed: 21962063
Copyright
Copyright 2011, Mary Ann Liebert, Inc.
History
Published in print: Fall 2011
Published online: 30 September 2011
Accepted: 21 April 2011
Received: 6 January 2011
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.